# HER2-PET Imaging in HER2-low Breast Cancers

> **NCT06732336** · PHASE1,PHASE2 · RECRUITING · sponsor: **Centre de recherche du Centre hospitalier universitaire de Sherbrooke** · enrollment: 40 (estimated)

## Conditions studied

- Breast Cancer Metastatic

## Interventions

- **DIAGNOSTIC_TEST:** 89Zr-trastuzumab

## Key facts

- **NCT ID:** NCT06732336
- **Lead sponsor:** Centre de recherche du Centre hospitalier universitaire de Sherbrooke
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-01
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06732336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06732336, "HER2-PET Imaging in HER2-low Breast Cancers". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06732336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*